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ABSTRACT
Objective: To investigate overnight variations in absolute
values and patterns of cytokines including interleukin 6
(IL6) and tumour necrosis factor a (TNFa) in rheumatoid
arthritis (RA), and to relate any changes to those
occurring in blood cortisol.
Methods: A total of 16 people (8 female) with active RA
and who had received no recent glucocorticoids were
admitted overnight. Blood samples were obtained at 13
time points between 21.00 and 10.00.
Results: The geometric mean IL6 concentration rose
significantly from 35 pg/ml at 22:00 to 64 pg/ml at 07:15
(repeated measures analysis of variance (ANOVA),
p,0.001). The geometric mean cortisol concentration
rose significantly overnight from 57 ng/ml at 01:00 to
229 ng/ml at 07:15 (repeated measures ANOVA,
p,0.001). Neither TNFa nor the other cytokines
measured changed significantly. Using cubic regression
modelling IL6 began to rise before cortisol (range 0.01 to
4.83 h) in eight participants and after cortisol (range 1.11
to 5.14 h) in three participants. In a random coefficient
model including data from all participants, the estimated
mean IL6 value began to rise 3.05 h before the estimated
mean cortisol value, with the IL6 peak occurring 0.70 h
before the cortisol peak.
Conclusion: The mean IL6 and cortisol concentrations
showed a significant overnight variation. Neither TNFa nor
the other cytokines measured changed significantly. In a
random coefficient model IL6 began to rise approximately
3 h, and reached a peak about 40 min, before cortisol.
These studies confirm that there are abnormalities in
plasma cortisol and IL6 concentrations and dynamics. The
data also link the overnight rise in IL6 to the circadian
variation in symptoms.
Patients with rheumatoid arthritis (RA) report
joint pain, swelling and stiffness on waking, which
improve as the morning progresses. This ‘‘early
morning stiffness’’ is considered a basic feature
pointing to inflammatory polyarthritis. Circadian
variation in symptoms and signs was first recorded
25 years ago
1 and animal models of inflammatory
arthritis show similar patterns.
23In RA synovitis is
driven in part by excessive production of cytokines
such as interleukin (IL)6 and tumour necrosis
factor a (TNFa).
4 The hypothalamic–pituitary–
adrenal (HPA) axis and its associated circadian
variations in cortisol are also implicated.
5 Since the
anti inflammatory properties of cortisol were first
described,
6 studies have failed to pinpoint a precise
defect in HPA control.
57 Sequential 24-h blood
samples suggest the HPA axis is unable to mount
an appropriately enhanced glucocorticoid response
to combat joint inflammation.
1 8–11
Serum concentrations of the proinflammatory
cytokines IL1b, IL6 and TNFa are raised in RA,
correlate with disease activity, and fall in response
to treatment.
12 13 Furthermore, recombinant IL6
dramatically stimulates the HPA axis.
14 Thus, there
is the potential for a link between the inflamma-
tory cytokines and circadian cortisol control.
Variation in IL6 in RA was reported when
measured every 3 h between 07:30–22:30
15 and
when measured over 24 h in five newly-diagnosed
patients a peak occurred at 07:00.
10 In two studies
of low dose glucocorticoid (prednisolone ,7.5 mg
equivalent) given at 02:00 compared with 07:30,
IL6 and symptoms were both improved at
08.00.
16 17 Thus, it is possible that variation in IL6
is related to variation in symptoms.
For TNFa and IL1b, one
11 of two studies
reporting overnight variations had a large differ-
ence between concentrations at the start and at the
end of the 24-h measurements (that should be
similar in circadian variation) and so may not have
been true biological variation. In the other,
18 the
variation in TNFa was not statistically significant.
A subsequent review
22 recalculated the values as
percentages of the 24-h mean, which overempha-
sises relatively small changes. Therefore, in order to
clarify the true nature and extent of nocturnal
variations in cytokines and their inter-relationship,
we measured several cytokines simultaneously at
frequent intervals during the night to determine
directly the absolute changes in cytokine levels,
their relative importance and their relationship to
blood cortisol. Our analysis focuses principally on
mathematical modelling of these patterns.
PATIENTS AND METHODS
Patients
The study was approved by the United Bristol
Healthcare NHS Trust (UBHT) Research Ethics
Committee and complied with the Helsinki
Declaration. Following written informed consent
16 patients with RA
19 and active disease (>3
swollen and >3 tender joints) were included who
had received no glucocorticoids by any route in the
previous 11 weeks (except patient 9: intra-articular
triamcinolone hexacetonide 40 mg 36 days earlier)
and no biological therapy at any time. All female
patients were postmenopausal. Three healthy
control volunteers served to ensure that blood
sample collection did not unduly disturb normal
circadian variation.
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Participants attended at 19:00 and generally remained on bed
rest. An intravenous cannula, usually inserted in the antecubital
fossa using local anaesthetic, was flushed immediately with
10 ml 0.9% saline (repeated before and after each blood sample)
and left for at least 1 h. Samples were taken at 21:00, 22:00,
23:00, 01:00, 03:00, 04:00, 05:00, 05:45, 06:30, 07:15, 08:00,
09:00 and 10:00, and the first 3 ml of each discarded to avoid
dilution. Low-level lighting was used when participants wanted
to sleep.
Clinical assessments
Assessments, performed between 08:00 and 10:00, included
tender and swollen 28-joint counts, morning stiffness (in min),
pain (on a 10 cm visual analogue scale: no pain to severe pain),
patient and clinician’s opinions of RA activity (on 10 cm visual
analogue scales: no disease activity to severe disease activity)
and the Hospital Anxiety and Depression Scale (HADS).
20
Height and weight were measured and the body mass index
(BMI) and 28-joint Disease Activity Score (DAS28) calculated.
Laboratory measurements
Plasma was separated and stored at –80uCw i t h i n1 ho f
collection. The routine hospital laboratory measured C-reactive
protein (CRP), plasma viscosity, haemoglobin and rheumatoid
factor. Total plasma cortisol was measured by in-house radio-
immunoassay using antisera raised in rabbits to cortisol-3-(O-
carboxymethyl) oxime (Bioclinical Services, Cardiff, UK). Tracer
was cortisol-3-(O-carboxymethyl) oximino-(2-[
125I]iodohistamine
(Amersham Pharmacia Biotech, Little Chalfont, UK). Intra- and
interassay coefficients of variation for cortisol were 5 and 8–12%
respectively. PlasmacytokineanalysesforTNFa,I L 1 b, IL6and IL8
wereperformedonaLuminex100 (Luminex, Austin, Texas,USA)
using ACS software (limit of detection 2.4 pg/ml), and for IL4,
IL5, IL10, IL13 and IFNc on a Bio-Rad Bio-Plex system (limit of
detection 0.01 pg/ml). Values below the limit of detection were
set at the limit. The intra assay variability was 2.9% for TNFa,
4.1% for IL6 and IL8 and 5.8% for IL1b. All plasma assays for
cortisol and cytokines were performed within 8 months.
Statistical analysis
Cortisol and cytokine concentrations were logarithmically
transformed (base 10) to remove skewness and summarised as
geometric means. Repeated measures analysis of variance
(ANOVA) was used to determine whether there were changes
in mean blood concentrations for each of the constituents over
time in the patient group as a whole (‘‘proc MIXED’’, SAS V.
8.2: SAS Institute, Cary, North Carolina, USA,) using either
antedependence or spatial power correlation structures.
Individual patterns of patient cortsol and IL6 were explored
using a cubic regression model (y=at
3+bt
2+ct+d, where t=time
in h) and the values and timings of troughs (minima) and peaks
(maxima) estimated from the model coefficients. We arbitrarily
discounted extrapolation more than 3 h outside the period of
observation. In a separate analysis of the patients as a group, a
random coefficient cubic regression model was fitted to all the
patient data using ‘‘proc MIXED’’. Each of the coefficients was
assumed to vary across patients and their means variances and
covariances estimated. In an exploratory analysis, cortisol and
IL6 concentrations in the eight patients with the highest scores
for morning stiffness (and separately, DAS28) were compared to
those in the eight with the lowest scores using the random
coefficient cubic regression model to compare the values and
timing of the troughs and peaks in the model, so as to identify
any change in pattern related to these two variables.
RESULTS
There were 8 men and 8 women (table 1), mean age 59 years
(range 38–75) and mean disease duration 10 years (range 0.2–
30); 15 were taking non-steroidal anti-inflammatory drugs and
12 taking disease-modifying antirheumatic drugs (methotrexate
6, sulphasalazine 2, methotrexate and sulphasalazine combina-
tion 2, leflunamide 1, penicillamine 1). The mean BMI was 26
(21–38). Three participants were obese with a BMI 30 (patients
5, 12 and 15) but had cortisol profiles that were similar to the
other non-obese participants (BMI,30). The mean HADS
anxiety score was 6.6 (1–12) and the HADS depression score
was 4.9 (1–13). One participant (patient 3) had a HADS
depression score of 13, indicating possible depression. This
participant and two others (patients 4 and 5) had HADS anxiety
scores of 12, 12 and 11, respectively, indicating possible anxiety.
Patients had a mean CRP of 53 mg/litre (10–159), plasma
viscosity 1.76 mPa (1.46–2.17), haemoglobin 12.2 g/dl (9.6–17.7)
and DAS28 5.05 (4.1–6.3); 11 (69%) were rheumatoid factor
positive and 12 (75%) had radiological evidence of erosions.
Laboratory results
The pattern of plasma cortisol variation in healthy volunteers
was similar to that previously reported: at 22:00 geometric
mean (95% CI) cortisol was 8.6 ng/ml (3.3 to 22.3) and at 05:45
the peak was 56.9 ng/ml (21.5 to 150.6). Individual cortisol
concentrations for patients with RA are shown in fig 1
(provided in detail in the supplementary material). The
minimum geometric mean was 56.9 ng/ml (37.2 to 87.1) at
01:00 and the maximum was 228.7 ng/ml (146.7 to 356.7) at
07:15 (repeated measures ANOVA p,0.001).
In healthy volunteers IL6 remained low for most of the night
but showed a small rise in the early hours of the morning. The
minimum geometric mean (95% CI) was 15.3 pg/ml (8.0 to
29.2) at 21:00 and the maximum was 19.7 pg/litre (7.4 to 52.0)
Table 1 Summary of clinical characteristics of patients*
Characteristic Mean (SD)
Male/female 8/8
Age (years) 59.1 (10.1)
Disease duration (years) 10.2 (9.2)
Erosive disease (%) 80
Haemoglobin (mg/dl) 12.2 (1.9)
Plasma viscosity (mPa) 1.8 (0.2)
C-reactive protein (mg/litre) 47.3 (46.3)
Rheumatoid factor positive (%) 70
Weight (kg) 72.3 (14.7)
Height (m) 1.7 (0.1)
BMI (kg/m
2) 26.2 (4.6)
Tender joint count 13.1 (6.6)
Swollen joint count 9.1 (4.9)
Early morning stiffness (min) 81.6 (82.8)
Patient global opinion (cm) 5.1 (2.2)
Pain (cm) 4.8 (2.5)
Clinician global opinion (cm) 5.9 (2.4)
DAS28 5.1 (0.8)
HADS (A) 6.6 (3.4)
HADS (D) 4.9 (3)
*Full details of all patients are available in the supplementary material.
BMI, body mass index; DAS28, 28-joint Disease Activity Score; HADS, Hospital
Anxiety and Depression Scale.
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Individual IL6 concentrations for patients with RA are shown
in fig 1 (summarised in the supplementary material). The
geometric mean changed significantly with time (repeated
measures ANOVA p,0.001), with a minimum of 34.5 pg/ml
(24.5 to 48.2) at 22:00 and a maximum of 64.4 pg/ml (41.2 to
100.6) at 07:15. The geometric means of TNFa did not change
significantly with time (p=0.202; see supplementary material).
Although other cytokines were difficult to analyse because of
values below the limit of detection, exploratory analyses failed
to detect significant overnight changes in IL1b, IL4, IL10 and
IL13 (see supplementary material). Too few IL5, IL8 and IFN
results were above the limit of detection for further assessment.
Statistical modelling
In one participant (patient 3) no minima or maxima could be
found for cortisol and in two (patients 12 and 13) the peak
would have fallen more than 3 h outside the period of
observation. The calculated values and times of the peaks and
Figure 1 Charts of individual data for all
patients showing interleukin (IL)6
(squares, left axis, pg/ml) and cortisol
(triangles, right axis, ng/ml).
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supplementary material. As IL6 was the only cytokine showing
statistically significant variations over time, regression model-
ling was applied to IL6 but not to the other cytokines. For IL6
there were two participants where no minima or maxima could
be found. There were three participants where the trough, and
two where the peak, would have fallen more than 3 h outside
the period of observation. Analysis of the remaining peaks and
troughs showed that the IL6 began to rise before cortisol (range
0.01–4.83 h) in eight patients and after cortisol (range 1.11–
5.14 h) for three patients.
The definitive random coefficient models including all (log
transformed) data from all patients for cortisol and for IL6 and
are shown in fig 2 and in the supplementary material. The rise
in mean IL6 concentration began 183 min before cortisol, with
peak IL6 occurring 42 min before cortisol, as illustrated using
the back-transformed model results in fig 3.
Clinical assessments
These showed correlation between tender and swollen joint
counts (r=0.76, p,0.01) and between each of these and the
DAS28 (r=0.88, p,0.01; r=0.88, p,0.01). DAS28 also
correlated with clinician global (r=0.54, p,0.05), but not
morning stiffness (r=0.32, not significant (NS)) or patient
global (r=0.29, NS). Morning stiffness correlated with patient
global (r=0.63, p,0.01) and pain (r=0.75, p,0.01). There was
no difference between high and low morning stiffness patients
in the models of overnight variation in cortisol or IL6. For
cortisol there was a significant difference (p=0.048) between
patients with high and low DAS28 scores. Patients with high
DAS28 scores had a cortisol trough of 48 ng/ml at 23:10
compared to those with lower DAS28 scores of 55 ng/ml at
00:30 (time difference 80 min) and peaks of 225 ng/ml at 07:38
and 247 ng/ml at 10:06 (time difference 148 min).
DISCUSSION
We measured 9 cytokines at frequent intervals during the night
in 16 patients with active RA, extending previous but less
extensive observations,
10 15 18 substantially increasing the num-
ber of patients for whom night-time cortisol and cytokine data
are available, and for the first time allowing a direct comparison
of the absolute changes in concentrations of the different
cytokines and their relative timing and importance. The
variation in cortisol was similar to that previously reported,
18 –
11 21 with the average trough at 23:47 and peak at 08:28. While
concentrations of TNFa, IL1b, IL4, IL6, IL8 and IL10 were raised
compared to normal volunteers (in agreement with the
literature) the only cytokine to show significant overnight
variation was IL6. In the majority of patients, plasma IL6 rose
before cortisol, although the reverse was found in a few
patients, possibly reflecting the timing of particular samples or a
poorly fitting statistical model. Taking all the patients together,
IL6 began to rise approximately 3 h before plasma cortisol, and
reached a peak about 40 min before cortisol. The results in our
normal volunteers showed concentrations similar to those
reported in the literature,
10 22 23 suggesting that the overnight
Figure 2 Model best fit lines for cortisol and interleukin (IL)6 with log
transformed values shown for each patient as dots.
Figure 3 Model best fit lines with 95% confidence intervals for cortisol
and interleukin (IL)6 with absolute values and minima and maxima
indicated.
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established circadian variations.
In this study, neither TNFa nor IL1b, nor any of the other
measured cytokines, showed significant overnight variation in
absolute values. This contrasts with two earlier reports
11 18 that
we believe were inconclusive (see above). In a review of the
cytokine data available at the time,
24 the conclusion that TNFa
showed circadian variation in patients with RA was dependant
on these two studies and on recalculation of TNFa concentra-
tions as percentages of the 24-h mean. This process ignores
absolute values and exaggerates small (and non-significant)
changes. Expressing the data from our study in a similar manner
appears to show marked TNFa variations, but in fact they are
minor and statistically non-significant when measured in
absolute terms. These difficulties in interpreting previous
studies emphasises the need for frequent and simultaneous
overnight sampling of all relevant cytokines, as reported here.
We chose cubic regression modelling for our principal
analysis. This allowed for fitting to a trough and a peak,
expected to occur overnight, and enabled us to estimate the
times and values for the troughs and peaks for individual
patients, and for the best fit model for all the patient data taken
together. Circadian modelling includes a 24-h period and for
these models additional harmonic terms would need to provide
an appropriate fit, increasing the number of parameters
estimated and demanding a greater range of data. Our
measurements were available for only 13 h, which was
sufficient for the cubic regression modelling, but would not
support circadian modelling. While in future studies it may be
advantageous to extend blood sampling to 24 h in order to
check circadian models against previously published work, the
possibility remains that concentrating on the times of interest
may provide greater precision.
Some authors have suggested that an intravenous cannula
may itself cause raised IL6 concentrations, possibly through
‘‘local’’ IL6 production.
25–29 This literature suggests the blood IL6
level may be increased by up to 1 pg/ml/h but that TNFa and
other cytokines are unaffected. We were able to take an extra
sample from the opposite arm at the end of each study for three
patients and three controls, and measure IL6 in the same assay
as the sample from their cannula. We found the opposite arm
sample to be 21% lower (on average), in accordance with this
theory of local production. This difference would affect the final
absolute values in our results, and deserves further investiga-
tion, but it would not affect the overall pattern of our results
and their interpretation.
Studies of this type demand a large commitment, in
particular from patients and healthy volunteers, so the number
of subjects, while comparable to other papers in the field, is
relatively small. The broad pattern of the results for IL6 and
cortisol will require confirmation, but lack of significant
changes in other cytokines was consistent across all the patients
studied. It is possible that repeated blood sampling disturbed
circadian variation. Many people with RA (including the
participants in this study) describe poor sleep in their usual
environment.
30 As the study progressed we collected informal
assessments suggesting disturbance was not great (data not
shown) and we will include formal measurements in future
studies. Some authors have suggested that age
22 and sleep
deprivation
23 31 alter the IL6 concentration. However, the
reported changes are small and unlikely to have made a
substantial difference to our measurements, which for IL6 were
up to 20 times normal and for TNFa 40 times normal. Our
study was not circadian because it was only overnight (13 h)
and did not last 24 h. This period was chosen for practical
reasons and because this was when the relevant changes in
cortisol and IL6 were likely to occur. Now the variations in
cortisol and IL6 are confirmed, future studies might best collect
24-h data.
Our clinical data showed that morning stiffness and DAS28
were poorly correlated and related to different patient char-
acteristics. This raised the possibility that they represent
different aspects of the disease and so we sought evidence for
this from within our cytokine measurements. Small but
significant difference in the timing of the overnight variations
in cortisol between patients with higher and lower DAS28
scores also raises the possibility that patterns of HPA response
are related to overall disease activity.
Of the many studies examining the HPA axis in RA,
57only
three include overnight data for relevant cytokines
10 11 18 and, as
discussed above, in two it is difficult to draw firm conclusions.
In the third, Crofford et al
10 studied five newly-diagnosed
patients and showed an IL6 increase preceded adrenocortico-
tropic hormone (ACTH), which preceded cortisol, with
approximately 1 h between each. Our data, in 16 patients with
a wide range of disease duration, support and expand upon this
finding. These studies confirm that there are abnormalities in
plasma cortisol and IL6 concentrations and dynamics. They also
link the overnight rise in IL6 to the circadian variation in
symptoms. We and others have suggested that a low dose of
glucocorticoid medication, delivered at 02:00 is more effective at
reducing symptoms and plasma IL6 concentration (in a single
08:00 blood sample) than an equivalent glucocorticoid dose
taken at 07:00.
16 17 If this were confirmed in future studies, it
may have important consequences for the dose and timing of
oral glucocorticoid treatment.
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